Naproxen 500mg + Domperidone 10mg Tablets are dual-active, solid oral medicines with a high amount of naproxen and a lower-strength component of domperidone within a single tablet. Since these two components are present in widely differing quantities, the influence on blend uniformity must be considered, especially when ensuring low-dose component uniformity. The role of powder formulator design parameters: particle size, flow and compaction characteristics, dissolution, and analytical control, underpin the development of this product. This combination provides a potential new product for companies new to tablet manufacturing within a well-structured Naproxen + Domperidone PCD Pharma Franchise range with suitable specifications.
There is a large difference in the quantities of API between the two products as the formulation contains a full 500mg of naproxen and 10mg of domperidone. Prior to formulation development the two APIs are tested for particle size, bulk density, flow, moisture content and excipient compatibility.
The excipient system has been selected to allow the tablets to blend evenly and to compress into tablets of an appropriate strength. Since naproxen accounts for the majority of the active load for the tablet, the formulation must not have poor powder-flow or compaction properties.
The manufacturing method chosen may be Direct Compression or another granulation technique suitable to the physical parameters of the materials. The goal is to produce a reproducible blend which consistently produces tablets within specification.
Because this component, the 10mg domperidone, comprises significantly less API than naproxen, this element deserves additional consideration. It is possible to improve the even distribution of the small dose API using a controlled premixing approach before incorporating it into the bigger formulation blend.
A geometric dilution or any other appropriate blending method can be used in the validated manufacturing process. Combining the two active materials and excipients with respect to their particle size can reduce segregation.
The of time, order of addition, blender load, and transfer conditions are determined during process development. Samples representing various positions in the blend should be analyzed to confirm uniformity.
Equally critical is the ability to keep powder in motion post-blending. Segregation can occur if powder is transferred too freely or vibrated excessively.
The compression step has to handle the comparatively high active load whilst ensuring that the table resist strength and general dosage-form performance criteria are maintained. Powder flow and compressibility data are obtained prior to the determination of compression parameters.
Compression force, machine speed, feed system setting and tooling arrangement. Effects: Tablet weight, hardness, thickness, friability and disintegration. These are developed to provide the desired balance of features.
Tablet weight, thickness, appearance, friability, and hardness can be monitored as in-process controls. When a film coated presentation is chosen, the coating process controls coating weight, so there is a uniform amount of coating on each tablet, and so that all the tablets look the same.
The final tablets shall be able to withstand the rigours of handling, packing, transportation and storage.
10mg Naproxen 500mg + Domperidone Tablets need analytical methods to make sure the active pharmaceutical ingredients are both in the finished product. This includes identification and assay testing.
Since the two APIs are at different strengths, the method must be sufficiently sensitive and selective for the lower strength DOM component and yet be capable of selectively quantifying naproxen.
The uniformity of dosage units may help to give further confidence in the uniformity of the individual tablets. The dissolution test is another key attribute of a finished product, as it looks at the disintegration of the active ingredients from the tablet matrix.
Additional quality attributes such as average weight, hardness, friability, disintegration, appearance, moisture and relevant relatedsubstance testing may also be applied.
Within stability study, the amount of testing and the parameters to be evaluated are established to establish whether the product remains the same chemically and physically to its initial state during the estimated shelf life. Assay, dissolution, degradation measures, appearance, hardness, moisture and others may be part of the monitoring according to product specifications.
Packaging The choice of the packaging depends on the nature of the formulation's instability. Depending on the stability profile, blister, strip, alu-alu or appropriate bottles may be used.
The packaging system should have appropriate protection against fading, taking account of light and moisture, as well as other environmental factors during transportation and storage.
Container-closure performance and packaging compatibility should be evaluated during development. The product label should be written in a manner that provides clear indication of the composition, strength, batch details, manufacturing information, expiry date, storage guidelines and any other regulatory information.
Naproxen 500mg + Domperidone 10mg Tablets are a biphasic product with a very large API ratio, which significantly increases the need for blend engineering and low-dose payload distribution. Well-designed powder processing, compression optimisation, analytical separation, dissolution assessment, stability evaluation and appropriate packing all help ensure final product consistency.
This mixture can be used by Pharma Franchise Companies for Pharma Product Development if their diversified PCD Pharma Franchise product line already has organized tablets with defined raw material specifications and controlled manufacturing processes.
Ensures Reproducible Batch Quality from API Qualification Premixing Final Blending Compression Analytical Testing Stability Testing Packing. Formulation Development Systematic method contributes to preserve the desired strength, dosage-unit uniformity, physical properties, and stability of the finished product tablets.
Naproxen 500mg + Domperidone 10mg Tablets with formulation, manufacturing, quality control, dissolution, stability and packaging details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech